{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T03:27:33Z","timestamp":1770521253275,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["309854"],"award-info":[{"award-number":["309854"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1245\/s10434-022-11947-w","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T16:03:18Z","timestamp":1654531398000},"page":"6673-6680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Surgical Management and Contralateral Breast Cancer Risk in Women with History of Radiation Therapy for Hodgkin Lymphoma: Results from a Population-Based Cohort"],"prefix":"10.1245","volume":"29","author":[{"given":"Elisheva R.","family":"Eisenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ipshita","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Skamene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Basik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Francois","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissa","family":"Ajjamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael N.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"11947_CR1","doi-asserted-by":"crossref","unstructured":"Hill DA, Gilbert E, Dores GaM, et al: Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 106:3358-3365, 2005.","DOI":"10.1182\/blood-2005-04-1535"},{"key":"11947_CR2","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015;373:2499\u2013511.","journal-title":"N Engl J Med."},{"key":"11947_CR3","first-page":"745","volume":"334","author":"S Bhatia","year":"1996","unstructured":"Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin\u2019s disease. 1996;334:745\u201351.","journal-title":"Breast cancer and other second neoplasms after childhood Hodgkin's disease."},{"key":"11947_CR4","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","volume":"32","author":"CS Moskowitz","year":"2014","unstructured":"Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32:2217\u201323.","journal-title":"J Clin Oncol."},{"key":"11947_CR5","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","volume":"95","author":"FE van Leeuwen","year":"2003","unstructured":"van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease. J Natl Cancer Inst. 2003;95:971\u201380.","journal-title":"J Natl Cancer Inst."},{"key":"11947_CR6","unstructured":"Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood AaYAC, Version 5.0. Monrovia, CA: Children's Oncology Group; October 2018; Available online: www.survivorshipguidelines.org."},{"key":"11947_CR7","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1200\/JCO.20.00562","volume":"38","author":"RL Mulder","year":"2020","unstructured":"Mulder RL, Hudson MM, Bhatia S, et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer From the International Guideline Harmonization Group. J Clin Oncol. 2020;38:4194\u2013207.","journal-title":"J Clin Oncol."},{"key":"11947_CR8","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1634\/theoncologist.2011-0451","volume":"17","author":"N Veit-Rubin","year":"2012","unstructured":"Veit-Rubin N, Rapiti E, Usel M, et al. Risk, characteristics, and prognosis of breast cancer after Hodgkin\u2019s lymphoma. Oncologist. 2012;17:783\u201391.","journal-title":"Oncologist."},{"issue":"Suppl. 3","key":"11947_CR9","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1016\/S0960-9776(11)70304-6","volume":"20","author":"M Intra","year":"2011","unstructured":"Intra M, Mattar D, Sangalli C, et al. Local therapy for breast cancer in malignant lymphoma survivors. Breast. 2011;20(Suppl. 3):S99-103.","journal-title":"Breast"},{"key":"11947_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1200\/JCO.2000.18.4.765","volume":"18","author":"SL Wolden","year":"2000","unstructured":"Wolden SL, Hancock SL, Carlson RW, et al. Management of breast cancer after Hodgkin\u2019s disease. J Clin Oncol. 2000;18:765\u201372.","journal-title":"J Clin Oncol."},{"key":"11947_CR11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1200\/JCO.1992.10.11.1674","volume":"10","author":"J Yahalom","year":"1992","unstructured":"Yahalom J, Petrek JA, Biddinger PW, et al. Breast cancer in patients irradiated for Hodgkin\u2019s disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol. 1992;10:1674\u201381.","journal-title":"J Clin Oncol."},{"key":"11947_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1748-717X-4-19","volume":"4","author":"MA Alm El-Din","year":"2009","unstructured":"Alm El-Din MA, Hughes KS, Raad RA, et al. Clinical outcome of breast cancer occurring after treatment for Hodgkin\u2019s lymphoma: case-control analysis. Radiat Oncol. 2009;4:19.","journal-title":"Radiat Oncol."},{"key":"11947_CR13","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.ijrobp.2011.03.013","volume":"82","author":"S Haberer","year":"2012","unstructured":"Haberer S, Belin L, Le Scodan R, et al. Locoregional treatment for breast carcinoma after Hodgkin\u2019s lymphoma: the breast conservation option. Int J Radiat Oncol Biol Phys. 2012;82:e145\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"11947_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00000421-200102000-00005","volume":"24","author":"M Deutsch","year":"2001","unstructured":"Deutsch M, Gerszten K, Bloomer WD, et al. Lumpectomy and breast irradiation for breast cancer arising after previous radiotherapy for Hodgkin\u2019s disease or lymphoma. Am J Clin Oncol. 2001;24:33\u20134.","journal-title":"Am J Clin Oncol."},{"key":"11947_CR15","doi-asserted-by":"crossref","unstructured":"Cutuli B, Kanoun S, Tunon De Lara C, et al. Breast cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: analysis of 214 cases. Crit Rev Oncol Hematol. 81:29-37, 2012.","DOI":"10.1016\/j.critrevonc.2011.01.005"},{"key":"11947_CR16","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1200\/JCO.2010.32.4079","volume":"29","author":"EB Elkin","year":"2011","unstructured":"Elkin EB, Klem ML, Gonzales AM, et al. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin\u2019s lymphoma: a multi-institutional, matched cohort study. J Clin Oncol. 2011;29:2466\u201373.","journal-title":"J Clin Oncol."},{"key":"11947_CR17","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","volume":"23","author":"JC Boughey","year":"2016","unstructured":"Boughey JC, Attai DJ, Chen SL, et al. Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks. Ann Surg Oncol. 2016;23:3100\u20135.","journal-title":"Ann Surg Oncol."},{"key":"11947_CR18","unstructured":"Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2016\/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019."},{"key":"11947_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.ijrobp.2017.03.016","volume":"98","author":"DW Arthur","year":"2017","unstructured":"Arthur DW, Winter KA, Kuerer HM, et al. NRG Oncology-Radiation Therapy Oncology Group Study 1014: 1-year toxicity report from a phase 2 study of repeat breast-preserving surgery and 3-dimensional conformal partial-breast reirradiation for in-breast recurrence. Int J Radiat Oncol Biol Phys. 2017;98:1028\u201335.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"11947_CR20","first-page":"1063","volume":"30","author":"L Overholser","year":"2016","unstructured":"Overholser L, Shagisultanova E, Rabinovitch RA, et al. Breast cancer following radiation for Hodgkin lymphoma: clinical scenarios and risk-reducing strategies. Oncology (Williston Park). 2016;30:1063\u201370.","journal-title":"Oncology (Williston Park)."},{"key":"11947_CR21","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ijrobp.2007.06.060","volume":"69","author":"WA Beckham","year":"2007","unstructured":"Beckham WA, Popescu CC, Patenaude VV, et al. Is multibeam IMRT better than standard treatment for patients with left-sided breast cancer? Int J Radiat Oncol Biol Phys. 2007;69:918\u201324.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"11947_CR22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/j.ijrobp.2009.10.006","volume":"78","author":"GR Borst","year":"2010","unstructured":"Borst GR, Sonke JJ, den Hollander S, et al. Clinical results of image-guided deep inspiration breath hold breast irradiation. Int J Radiat Oncol Biol Phys. 2010;78:1345\u201351.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"11947_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ijrobp.2015.09.018","volume":"95","author":"JA Bradley","year":"2016","unstructured":"Bradley JA, Dagan R, Ho MW, et al. Initial report of a prospective dosimetric and clinical feasibility trial demonstrates the potential of protons to increase the therapeutic ratio in breast cancer compared with photons. Int J Radiat Oncol Biol Phys. 2016;95:411\u201321.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"11947_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ijrobp.2008.04.068","volume":"72","author":"SK Basu","year":"2008","unstructured":"Basu SK, Schwartz C, Fisher SG, et al. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin\u2019s disease. Int J Radiat Oncol Biol Phys. 2008;72:34\u201340.","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"444\u201355","key":"11947_CR25","first-page":"W144","volume":"152","author":"TO Henderson","year":"2010","unstructured":"Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152(444\u201355):W144\u201354.","journal-title":"Ann Intern Med."},{"key":"11947_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0167-8140(01)00337-1","volume":"59","author":"B Cutuli","year":"2001","unstructured":"Cutuli B, Borel C, Dhermain F, et al. Breast cancer occurred after treatment for Hodgkin\u2019s disease: analysis of 133 cases. Radiother Oncol. 2001;59:247\u201355.","journal-title":"Radiother Oncol."},{"key":"11947_CR27","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317:2402\u201316.","journal-title":"JAMA."},{"key":"11947_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41523-020-00202-8","volume":"6","author":"D Giardiello","year":"2020","unstructured":"Giardiello D, Kramer I, Hooning MJ, et al. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. NPJ Breast Cancer. 2020;6:60.","journal-title":"NPJ Breast Cancer."},{"key":"11947_CR29","doi-asserted-by":"crossref","unstructured":"Nichols HB, Berrington de Gonzalez A, Lacey JV, Jr., et al. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 29:1564-9, 2011.","DOI":"10.1200\/JCO.2010.32.7395"},{"key":"11947_CR30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1097\/SAP.0000000000002087","volume":"84","author":"B Freniere","year":"2020","unstructured":"Freniere B, Irwin T, Guldbrandsen G, et al. Outcomes following breast reconstruction in patients with prior mantle radiation for treatment of Hodgkin\u2019s lymphoma. Ann Plast Surg. 2020;84:507\u201311.","journal-title":"Ann Plast Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11947-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11947-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:14:39Z","timestamp":1663773279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11947-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11947"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11947-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"28 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lissa Ajjamada reports research funding from Incyte pharmaceuticals and honoraria from Merck, and Bristol Myers Squibb outside the submitted work. Anna Weiss reports research funding from Myriad Laboratories, Inc. outside the submitted work. Jean-Francois Boileau reports honoraria from Roche, Novartis, Genomic Health, Pfizer, Allergan, and Merck; personal fees from Roche, Genomic Health, NanoString Technologies, Pfizer, Eli Lilly, Novartis, and Merck; and travel support from Roche, GlaxoSmithKline, Novartis, Pfizer, and Lifecell outside the submitted work. The remaining authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}